This Treatment May Help Depression in Older People
When a doctor prescribes aripiprazole (Abilify), an antipsychotic drug, for an older person already taking the antidepressant venlafaxine, that combination can help ease depression that doesn't get better with typical treatment, according to a new study. (Source: WebMD Health)
Source: WebMD Health - October 1, 2015 Category: Consumer Health News Source Type: news

Add-On Aripiprazole Helps Manage Treatment-Resistant Depression in Elders (FREE)
By Amy Orciari Herman Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH Adding the atypical antipsychotic aripiprazole (Abilify) to an antidepressant can help older adults with difficult-to-treat depression, a Lancet study finds. Over … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - September 28, 2015 Category: Primary Care Source Type: news

FDA to review Proteus ‘smart pill’ with Otuka’s Abilify anti-depressant
Otsuka Pharmaceutical (TYO:4578) and Proteus Digital Health said yesterday that the FDA will review a combination of the Proteus “smart pill” and Otsuka’s Abilify anti-depressant drug. The companies said the FDA accepted their new drug application for the drug-device combination, using the Proteus ingestible sensor and Otsuka’s aripiprazole drug in patients with serious mental illnesses such as major depressive disorder, bipolar disorder and schizophrenia. It’s the 1st time the federal safety watchdog has reviewed a drug-device combo designed to measure adherence. The Proteus pill is design...
Source: Mass Device - September 11, 2015 Category: Medical Equipment Authors: Brad Perriello Tags: Drug-Device Combinations Otsuka Pharmaceutical Proteus Digital Health Source Type: news

Proteus, Otsuka submit first commercial drug with built-in sensor to FDA
After years of using its digital health feedback system in clinical trials and studies, Proteus Digital Health, and partner Otsuka Pharmaceuticals, are poised to launch the first mass market drug to incorporate Proteus’s ingestible sensor. The companies have submitted a sensor-embedded version of the antidepressant Abilify for FDA approval. “Today, patients suffering from severe mental […] (Source: mobihealthnews)
Source: mobihealthnews - September 10, 2015 Category: Information Technology Authors: Jonah Comstock Tags: Government/Regulation Pharma Uncategorized Abilify ingestible sensor Otsuka Pharmaceuticals Proteus Digital Health Proteus Digital Health feedback system Source Type: news

CHMP Backs Three Generics for Major Mental IllnessesCHMP Backs Three Generics for Major Mental Illnesses
The EMA committee gives green light to Duloxetine Zentiva, Aripiprazole Sandoz, and Pregabalin Accord. Medscape Medical News (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - June 26, 2015 Category: Psychiatry Tags: Psychiatry News Source Type: news

Otsuka loses lawsuit challenging FDA approval of generic Abilify
(Reuters) - Otsuka Pharmaceutical Co Ltd has lost a lawsuit challenging the U.S. Food and Drug Administration's decision to allow generic versions of the company's antipsychotic drug Abilify. (Source: Reuters: Health)
Source: Reuters: Health - May 28, 2015 Category: Consumer Health News Tags: healthNews Source Type: news

NeuroBreak: Denial for Survival, Generic Abilify
(MedPage Today) -- News and commentary from the world of neurology and neuroscience. (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - May 5, 2015 Category: Neurology Source Type: news

Monthly News Roundup - April 2015
FDA Approves First-Time Generic for BMS’s Abilify Abilify (aripiprazole) is a blockbuster atypical antipsychotic drug used to treat the mental illnesses schizophrenia and bipolar disorder. On April 28th, the U.S. Food and Drug Administration... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 30, 2015 Category: Pharmaceuticals Source Type: news

FDA Approves First Generic Versions of Abilify (FREE)
By the Editors The FDA on Tuesday approved the first generic versions of the atypical antipsychotic Abilifiy (aripiprazole) for … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - April 30, 2015 Category: Primary Care Source Type: news

FDA grants approval for generic version of antipsychotic drug Abilify
The US Food and Drug Administration (FDA) has granted approval for the first generic versions of Abilify (aripiprazole), which is an atypical antipsychotic drug to treat schizophrenia and bipolar disorder. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - April 29, 2015 Category: Pharmaceuticals Source Type: news

FDA Okays First Aripiprazole GenericsFDA Okays First Aripiprazole Generics
The FDA has approved the first generic versions of the atypical antipsychotic aripiprazole. FDA Approvals (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - April 29, 2015 Category: Psychiatry Tags: Psychiatry News Alert Source Type: news

FDA Approves Generic Abilify: Teva, Alembic, Hetero, Torrent Come to Market
Generic aripiprazole is an atypical antipsychotic drug approved to treat schizophrenia and bipolar disorder (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - April 28, 2015 Category: Pharmaceuticals Source Type: news

FDA approves generic versions of antipsychotic drug Abilify
(Reuters) - The U.S. Food and Drug Administration said it approved the first copycat versions of Otsuka Pharmaceutical Co Ltd's antipsychotic drug, Abilify. (Source: Reuters: Health)
Source: Reuters: Health - April 28, 2015 Category: Consumer Health News Tags: healthNews Source Type: news

FDA approves first generic Abilify to treat mental illnesses
The U.S. Food and Drug Administration today approved the first generic versions of Abilify (aripiprazole). Generic aripiprazole is an atypical antipsychotic drug approved to treat schizophrenia and bipolar disorder. (Source: Food and Drug Administration)
Source: Food and Drug Administration - April 28, 2015 Category: American Health Source Type: news

FDA Approves First Generic Abilify (aripiprazole) to Treat Mental Illnesses
April 28, 2015 -- The U.S. Food and Drug Administration today approved the first generic versions of Abilify (aripiprazole). Generic aripiprazole is an atypical antipsychotic drug approved to treat schizophrenia and bipolar disorder. Alembic... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 28, 2015 Category: Pharmaceuticals Source Type: news